Evidence map›Paper›PMID 36207642›Full record

ArticleThe AAPS journal2022

Preclinical InVivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T-Cell Bispecific in Combination with Anti-PD-L1.

Javier Sánchez, Valeria Nicolini, Linda Fahrni, Inja Waldhauer, Antje-Christine Walz, Candice Jamois, Stephen Fowler, Silke Simon, Christian Klein, Pablo Umaña and 2 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in The AAPS journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Javier SánchezRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070, Basel, Switzerland. javier.sanchez_fernandez@roche.com.ORCID http://orcid.org/0000-0002-8279-6916
Valeria NicoliniRoche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.
Linda FahrniRoche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.
Inja WaldhauerRoche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.
Antje-Christine WalzRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070, Basel, Switzerland.
Candice JamoisRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070, Basel, Switzerland.
Stephen FowlerRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070, Basel, Switzerland.
Silke SimonRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070, Basel, Switzerland.
Christian KleinRoche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.
Pablo UmañaRoche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.
Lena E FribergDepartment of Pharmacy, Uppsala University, Uppsala, Sweden.
Nicolas FrancesRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070, Basel, Switzerland.
Roche (Switzerland) · CHUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TYRP1-TCB is a CD3 T-cell bispecific (CD3-TCB) antibody for the treatment of advanced melanoma. A tumor growth inhibition (TGI) model was developed using mouse xenograft data with TYRP1-TCB monotherapy or TYRP1-TCB plus anti-PD-L1 combination. The model was translated to humans to inform a refined clinical strategy. From xenograft mouse data, we estimated an EC

Indexed as

Antibodies, BispecificMelanomaAnimalsCell Line, TumorHumansMiceT-LymphocytesAntibodies, BispecificCD3-bispecificsCheckpoint inhibitorsCombinationPKPD modeling

Identifiers

PMID36207642
OpenAlexW4303471051

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.